Abstract
Beta-adrenergic blocking agents exert their major effects through the beta adrenoceptors in the heart and peripheral vasculature. Both heart rate and myocardial contractility are reduced with beta blockade. Beta receptors are also found in a wide range of other tissues. These agents are generally well tolerated, and are widely used for various cardiovascular and other clinical conditions.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Selected Bibliography
Australia/New Zealand Heart Failure Research Collaborative Group: Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997. 349: 375–380.
Beta-Blocker Heart Attack Trial Research Group: A randomized trial of propranolol in patients with acute myocardial infarction. JAMA 1982, 247: 1707–1713.
Black JW: Ahlquist and the development of beta-adrenoceptor antagonists. Postgrad Med J 1976. 52 (suppl 4): 11–13.
Boissel JP. Leizorovicz A, Picolet H, et al.: Secondary prevention after high-risk acute myocardial infarction with low-dose acebutolol. Am J Cardin! 1990, 66:251–260.
Carson PE: 3-blocker therapy in heart failure: pathophysiology and clinical results. Curr Prob Card 1999 24: 42I-460.
Cavusoglu E, Frishman WH: Sotalol: a new 3-adrenergic blockers for ventricular arrhythmias. Prog Cardiovasc Dis 1995. 37: 423–440.
Chadda K. Goldstein S. Byington R, Curb JD: Effects of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation 1986, 73: 503–510.
CIBIS Investigators and Committees: A randomized trial of ß blockade in heart failure: The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994. 90: 1765–1773.
CIBIS II Investigators and Committees: The Cardiac Insufficiency Bisoprolol Study II (C1BIS Il): a randomized trial. Lancet 1999, 353: 9–13.
Coope J, Warrender TS: Randomised trial of treatment of hypertension in elderly patients in primary care. Br Med J 1986, 293: 1145–1148.
Cruickshank JM: Measurement and cardiovascular relevance of partial agonist activity (PAA) involving betal- and beta2-adrenoceptors. Pharinacol Ther 1990, 46: 199–242.
Cruickshank JM. Pennell K. Sorman A, et al.: Low mortality from all causes, including myocardial infarction, in well-controlled hypertensives treated with a beta blocker plus other antihyper-tensives. J Hypertens 1987.5:489–498.
DiBona GF, Sawin LL: Effect of metoprolol administration on renal sodium handling in experimental heart failure. Circulation 1999, 100: 82–86.
Dwyer N, Walter P, Cruickshank JM, et al.: Effect of propranolol and phentolamine on myocardial necrosis after subarachnoid haemorrhage. Br Med J 1978. 2:990–992.
Engelmeier RS. O’Connell JB, Walsh R, et al.: Improvements in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy. Circulation 1985, 72:536–546.
Frishman WH: Secondary prevention of myocardial infarction: the roles of beta-adrenergic blockers, calcium-channel blockers, angiotensin converting enzyme inhibitors and aspirin. In Triggering of Acute Coronary Syndromes: Implications for Prevention. Edited by Willich SN, Muller JE. Dordrecht: Kluwer Academic Publishers; 995: 367–394
Frishman WH: Alpha- and beta-adrenergic blocking drugs. In Cardiovascular Pharnutcotherapeutics. Edited by Frishman WH, Sonnenblick EH. New York: McGraw Hill; 1997: 59–94.
Frishman WH: Alpha- and beta-adrenergic blocking drugs. In Cardiovascular Pharmacotherapeutics Companion Handbook. Edited by Frishman WH, Sonnenblick EH. New York: McGraw Hill; 1998: 23–64.
Frishman WH: Carvedilol. N Engl J Med 1998, 339: 1759–1765.
Frishman WH: 3-Adrenergic blockers. In Hypertension Primer, edn 2. Edited by lzzo JL Jr, Black HR. Dallas: American Heart Association; 1998: 362–365.
Frishman WH. Bums FJ, Mroczek WJ. et al.: First-line therapy option with low-dose bisoprolol fumarate and low-dose hydrocholorothiazide in patients with stage I and stage II systemic hypertension. J Clin Pharacol 1995, 35: 182–188.
Frishman WH, Bryzinski BS, Coulson LR, et al.: A multifactorial trial design to assess combination therapy in hypertension: treatment with bisoprolol and hydrochlorothiazide. Arch Intern Med 1994, 154:1461–1468.
Frishman WH, Cheng A: Secondary prevention of myocardial infarction: the role of 3-adrenergic blockers and angiotensin converting enzyme inhibitors: based on symposium Agents to Prevent Acute Coronary Disease. Am Heart J 1999, I37: S25 - S34.
Frishman WH, Christiana J: The current use of beta blockers in cardiovascular disease. In Cardiology Clinics Annual o Drug Therapy, vol 2. Edited by Crawford MN. Philade phis: W.B. Saunders; 1998: 37–59.
Frishman WH, Murthy VS. Strom JA, Hershman D: Ult short-acting 13-adrenergic blocking drugs. In Cardiovascular Drug Therapy, edn 2. Edited by Messerli FH. Philadel- phia: W.B. Saunders; 1996: 507–516.
Frishman WH, Skolnick AE: Secondary prevention post infarction: the role of G3-adrenergic blockers, calcium-channel blockers and aspirin. In Acute Myocardial Infarction, edn 2. Edited by Gersh BJ, Rahimtoola SH. New York: Chapman and Hall; 1996: 766–796.
Frishman WH, Sonnenblick EH: 3-Adrenergic blocking drugs and calcium channel blockers. In HurstsThe Heart, edn 9. Edited by Alexander RW, Schlant RC, Fuster V. New York: McGraw Hill: 1998: 1583–1618.
Goldstein S, Hjalmarson A: Metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF): an update after completed randomization: The International Steering Committee on behalf of the MERIT-HF Study Group [abstract]. Circulation 1998, 98 (Suppl): 1–364.
Hjalmarson A, Herlitz I, Holmbert S. et al.: The Goteborg Metoprolol Trial: effects on mortality and morbidity in acute myocardial infarction. Circulation 1983,67 (Suppl I):136–132.
Hohnloser SH, Meinertz T, Klingenheben T. et al.: Usefulness of esmolol in unstable angina pectoris. Am J Cardiol 1991, 67: 1319–1323.
ISIS-1 Collaborative Group: Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 1986, îi:57–66.
Kjekshus J: Comments: beta blockers and heart rate reduction: a mechanism of benefit. Eur Heart J 1985, 6 (Suppl A): 29–30.
Kjekshus J, Gilpin E, Cali G, et al.: Diabetic patients and beta blockers after acute myocardial infarction. Eur Heart J 1990,11:43–50.
Lubsen J, Tijssen JGP, Study Group: Efficacy of nifedipine and metoprolol in the early treatment of unstable angina in the coronary care unit: findings from the Holland Interuniversity NifedipinelMetoprolol Trial (HINT). Am J Cardiol 1987. 60: 18A - 25A.
Man In’t Veld AJ, van den Meiracker AH: Effects of antihypertensive drugs on cardiovascular haemodynamics. In Hypertension. Edited by Laragh JH, Brenner BM. New York: Raven Press; 1990, 2117–2130.
Mason JW for the Electrophysiologic Study Versus Electrocardiographic Monitoring Investigators (ESVEM): A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N Engl J Med 1993, 329: 452–458.
McAinsh H. Cruickshank JM: Beta blockers and the central nervous system side effects. Pharmacol Ther 1990, 46: 163–197.
MERIT-HF Study Group: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999, 353: 2001–2007.
Miall WE, Greenberg D: The Medical Working Party on mild to moderate hypertension: the influence of thiazide and beta-blocker treatment on ECG findings. In Mild Hypertension: Is There Pressure to Treat? An Account of the MRC Trial. Cambridge: Cambridge University Press; 1987: 78–94; 181–185.
MIAMI Trial Research Group: Metoprolol in Acute Myocardial Infarction (MIAMI): a randomised placebo-controlled international trial. Eur Heart J 1985. 6: 199–226.
Mohindra SK, Udeani GO: Intravenous esmolol in acute aor-tic dissection. Ann Plutrmacother 1991. 25: 735–738.
MRC Working Party: MRC Trial of Treatment of Mild Hypertension: principal results. Br Med J1985,291:97–104.
Norwegian Multicentre Study Group: Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981, 304: 801–807.
Opie LH, Sonnenblick EH, Frishman WH, Thadani U: Beta-blocking agents. In Drug.s for the Heart, edn 4. Edited by Opie LH. Philadelphia: W.B. Saunders; 1995: 1–30.
Packer M, Bristow MR, Cohn JN, et al.: The effect of carvedilol on morbidity and mortality in patient with chronic heart failure. N Engl J Med 1996, 334:1349–1355.
Pepine CJ, Cohn PF, Deedwania PC. et al.: Effects of treatment on outcome in asymptomatic and mildly symptomatic patients with ischemia during daily life: The Atenolol Silent Ischemia Study (ASIST). Circulation 1994.90:762–768.
Quyyumi AA, Crake T, Wright CM, et al.: Medical treatment of patients with severe exertional and rest angina in a double-bind comparison of beta blocker. calcium antagonist and nitrate. Br Heart J 1987, 57:505–511.
Rapaport E: Should beta blockers be given immediately and concomitantly with thrombolytic therapy in acute myocardial infarction? Circulation 1991, 83: 695–697.
Sandberg A, Blomqvist 1, Jonsson UE. Lundborg P: Pharmacokinetic and pharmacodynamic properties of a new controlled-release formulation of metoprolol: a comparison with conventional tablets. Eur J Clin Pharmacol 1988, 33 ( Suppl ): S9-S 14.
Sharma S, Mitra S, Grover VK, et al.: Esmolol blunt the haemodynamic responses to tracheal intubation in treated hypertensive patients. Can J Anaesih 1996.43:778–782.
The SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991, 265: 3255–3264.
Smerling A, Gersony WM: Esmolol for severe hypertension following repair of aortic coarctation. Crit Care Med 1990, 18: 1288–1290.
Wikstrand J. Wamold I, Olsson G, et al.: Primary prevention with metoprolol in patients with hypertension. JAMA 1988, 159:1976–1982.
Wilhelmsen L, Berglund G, Elmfeldt D. et al.: Beta blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hvpertens 1987, 5:561–572.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer Science+Business Media New York
About this chapter
Cite this chapter
Frishman, W.H., Cheng-Lai, A., Chen, J. (2000). Beta-Adrenergic Blockers. In: Frishman, W.H., Cheng-Lai, A., Chen, J. (eds) Current Cardiovascular Drugs. Current Medicine Group, London. https://doi.org/10.1007/978-1-4615-6767-7_8
Download citation
DOI: https://doi.org/10.1007/978-1-4615-6767-7_8
Publisher Name: Current Medicine Group, London
Print ISBN: 978-1-57340-135-7
Online ISBN: 978-1-4615-6767-7
eBook Packages: Springer Book Archive